Nxera Pharma to receive $8.6m milestone from Lilly-owned Centessa

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A white and grey ophthalmic autorefractor is centered in a brightly lit, clean eye examination room with blurred wall art, a grey chair, and wooden cabinetry in the background.

Nxera Pharma has announced it will receive a US$8.6 million milestone payment from Centessa Pharmaceuticals after Centessa's selective orexin receptor 2 (OX2R) agonist portfolio reached a late-stage development trigger. The payment will be recognised as revenue in the third quarter of Nxera's fiscal year ending 31 December 2026.

Centessa, now a wholly-owned subsidiary of Eli Lilly following Lilly's acquisition completed on 24 June 2026, holds a clinical-stage OX2R agonist pipeline targeting sleep-wake regulation disorders and related neurological conditions. The collaboration originated from a research agreement between Nxera and Centessa; under its terms, Nxera retains the right to receive further development and commercialisation milestones as well as royalties should any programme reach market.

The deal and what triggered it

The release does not specify which molecule or clinical stage triggered the milestone, nor does it disclose the total potential value of the collaboration or how many further milestone payments remain. Christopher Cargill, President and Chief Executive of Nxera Pharma, said the company was pleased to see "progress in the clinic and more broadly across the OX2R agonist pipeline" and that it looks forward to announcing further updates as key milestones are reached.

Lilly's acquisition of Centessa brought the OX2R portfolio under the umbrella of one of the world's largest pharmaceutical companies, a development that materially changes the commercial calculus for Nxera. Large-cap backing typically accelerates late-stage trials and lowers the risk of a programme stalling for funding reasons, which should be constructive for Nxera's downstream royalty and milestone stream.

Market context and competitive landscape

The orexin receptor field has seen a sharp rise in industry interest following the commercial success of dual orexin receptor antagonists (DORAs) in insomnia, led by Merck's suvorexant and Idorsia's daridorexant. The therapeutic hypothesis for OX2R agonism runs in the opposite direction: rather than blocking the orexin system to promote sleep, an OX2R agonist is designed to activate wake-promoting pathways, with potential relevance to disorders such as narcolepsy and idiopathic hypersomnia.

Jazz Pharmaceuticals, with its oxybate franchise, and Takeda, with pitolisant (a histamine H3 inverse agonist that indirectly modulates orexin tone), are the dominant commercial players in hypersomnia today. A selective OX2R agonist with a clean tolerability profile would represent a mechanistically distinct option, though clinical validation in late-stage studies remains the critical gating factor. Several academic groups and smaller biotechs are exploring similar targets, making the clinical dataset that Lilly is presumably generating a closely watched variable in the field.

For Nxera, the $8.6 million receipt is a meaningful non-dilutive cash inflow for a company of its size, and the structure of the deal means that upside scales with Lilly's clinical progress. Investors will be looking for Nxera to clarify the remaining milestone schedule and the royalty rate band, neither of which was disclosed in this announcement. The next substantive catalyst is likely to be a trial readout or regulatory submission from Lilly that unlocks a further payment under the collaboration agreement.

Sector

Topic

Geography